about
Effect of atypical antipsychotics on fetal growth: is the placenta involved?Modulation ofTcf7l2 expression alters behavior in mice.Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Gene expression profiling in rodent models for schizophrenia.Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.Diabetes and schizophrenia 2005: are we any closer to understanding the link?Association between antipsychotic drugs and diabetes.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management.Metabolic syndrome in patients with severe mental illness in GorganMetabolic syndrome in people with schizophrenia: a review.A UK audit of screening for the metabolic side effects of antipsychotics in community patients.Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?Telemedicine as a tool to mitigate cardiometabolic risk associated with serious mental illness.Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1.Clustering of schizophrenia with other comorbidities--what can we learn?Diabetes: increasing the knowledge base of mental health nurses.Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5'-monophosphate-activated protein kinase.Factors influencing cardiometabolic monitoring practices in an adult community mental health service.Prevalence of metabolic syndrome among inpatients with schizophrenia.Chlorpromazine attenuates pancreatic beta-cell function and mass through IRS2 degradation, while exercise partially reverses the attenuation.Assessment of cardiovascular risk in an Italian psychiatric outpatient sample: A chart review of patients treated with second-generation antipsychotics.Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden.Effect of risperidone on serum lipids and cerebrovascular mortality among elderly dementia patients with associated behavioral disturbances.Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics.Metabolic Syndrome Prevalence and Reduction in Inmates Prescribed Antipsychotic Medications.
P2860
Q27012948-E4B83B56-3356-4367-9851-2234EA586C55Q34064796-23B0D1B1-8ED2-4509-8E12-2E7F176D160CQ34610608-3F2F2B16-CF50-4D57-9101-11A52A2B5FC3Q34829319-191D6060-B558-48C4-A027-2356E3FFE3F2Q35290463-CD8E8EC3-786B-4571-B95A-9DD26EF178CAQ36040749-704602E5-6EDA-410A-AB37-F74DF489EFCDQ36211690-70680C86-9ED1-4DA5-A50B-6C0A0D5509E9Q36310303-3F5595DF-2DEC-4BA8-96C1-8392B26D45A3Q36382695-A205D742-EDAA-4425-B300-18D08F5D3135Q36425995-0FFF29A1-19C0-4A5A-9520-C94DBAD3525DQ36646218-8474A456-F8B7-447A-AE3E-E262BEBD146FQ36657453-C81B8B4F-C188-456E-973D-3546BA0E34A8Q37129646-0426DB9E-DBE2-4CC4-8220-D7749C196224Q37427104-68F8981A-6122-4F67-ACB1-9004F571F603Q38015698-196C189B-11FD-4F66-8C07-BE4E3B10B7DEQ38260282-89BD1E88-9737-4FA9-B91C-AD80ACB6F1DFQ38879553-9B838D59-EBBA-4912-AB72-3F59A47DD4B0Q43158437-A42E5F78-80F3-434D-9FB4-BEE4B1502A2EQ43792669-FA05E816-3F64-4F7A-9A1A-1D5DB5399BEAQ44650829-F906EF4D-B042-460F-946F-8645AF23F5B0Q44986103-A59C9A7B-0D4D-4FCE-A2DB-FA7916D1058BQ45771183-1178D946-B704-4C41-A73C-0B4791942057Q45974475-E247C0FE-A683-44E2-9480-AEC6B91BC4FBQ46727046-B7C1880B-71BD-4CFC-A21C-E9BBF974787AQ47568514-704BF4C3-CD22-45DD-A499-CF46130C94EDQ50551373-BBBBAD48-4864-4DF9-A367-94ADC07B84ECQ51456912-FA19CCD4-AB19-4687-B961-30CE7DFC1B6CQ51818927-41CB2D21-9B3B-4452-8121-F8A5750B4619Q53509978-F531B1FA-74B8-46F9-8EA0-956840B01BDE
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Schizophrenia, the metabolic syndrome and diabetes.
@ast
Schizophrenia, the metabolic syndrome and diabetes.
@en
type
label
Schizophrenia, the metabolic syndrome and diabetes.
@ast
Schizophrenia, the metabolic syndrome and diabetes.
@en
prefLabel
Schizophrenia, the metabolic syndrome and diabetes.
@ast
Schizophrenia, the metabolic syndrome and diabetes.
@en
P2093
P2860
P1433
P1476
Schizophrenia, the metabolic syndrome and diabetes.
@en
P2093
P2860
P304
P356
10.1111/J.1464-5491.2004.01199.X
P577
2004-06-01T00:00:00Z